

PATENT COOPERATION TREATY

PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference 47517-768601		FOR FURTHER ACTION see Form PCT/ISA/220 as well as, where applicable, item 5 below.	
International application No. PCT/US2023/083985	International filing date (<i>day/month/year</i>) 14 December 2023 (14.12.2023)	(Earliest) Priority Date (<i>day/month/year</i>) 05 January 2023 (05.01.2023)	
Applicant HARPOON THERAPEUTICS, INC.			

This international search report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This international search report consists of a total of 9 sheets.

☐ It is also accompanied by a copy of each prior art document cited in this report.

1. Basis of the report

a. With regard to the **language**, the international search was carried out on the basis of:

- ☒ the international application in the language in which it was filed.
☐ a translation of the international application into _____ which is the language of a translation furnished for the purposes of international search (Rules 12.3(a) and 23.1(b)).

b. ☐ This international search report has been established taking into account the **rectification of an obvious mistake** authorized by or notified to this Authority under Rule 91 (Rule 43.6bis(a)).

c. ☒ With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, see Box No. I.

2. ☒ **Certain claims were found unsearchable** (see Box No. II).

3. ☒ **Unity of invention is lacking** (see Box No. III).

4. With regard to the **title**,

- ☒ the text is approved as submitted by the applicant.
☐ the text has been established by this Authority to read as follows:

5. With regard to the **abstract**,

- ☒ the text is approved as submitted by the applicant.
☐ the text has been established, according to Rule 38.2, by this Authority as it appears in Box No. IV. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

6. With regard to the **drawings**,

- a. the figure of the **drawings** to be published with the abstract is Figure No. 26
☒ as suggested by the applicant.
☐ as selected by this Authority, because the applicant failed to suggest a figure.
☐ as selected by this Authority, because this figure better characterizes the invention.
- b. ☐ none of the figures is to be published with the abstract.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US2023/083985

Box No. I **Nucleotide and/or amino acid sequence(s) (Continuation of item 1.c of the first sheet)**

1. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international search was carried out on the basis of a sequence listing:
 - a. ☐ forming part of the international application as filed.
 - b. ☒ furnished subsequent to the international filing date for the purposes of international search (Rule 13ter.1(a)),
☒ accompanied by a statement to the effect that the sequence listing does not go beyond the disclosure in the international application as filed.
2. ☐ With regard to any nucleotide and/or amino acid sequence disclosed in the international application, this report has been established to the extent that a meaningful search could be carried out without a WIPO Standard ST.26 compliant sequence listing.
3. Additional comments:

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☒ Claims Nos.: **4-36, 40-64, 68-84, 87-100, 104-115, 122-127, 131-136, 140-150**
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1. In order for all inventions to be examined, the appropriate additional examination fees need to be paid.

Group I+: claims 1-3, 37-39, 65-67, 85, 86, 101-103, 116-121, 128-130, and 137-139 are drawn to TROP2 binding domains, conditionally active TROP2 binding proteins, multivalent proteins, active drugs, processes for producing a multivalent protein, processes for producing an active drug, methods of increasing a therapeutic index of a TROP2 binding domain, methods of increasing a therapeutic index of a TROP2 binding protein, methods of increasing a therapeutic index of a TROP2 binding protein, and TROP2 targeting conditionally active multispecific proteins.

The first invention of Group I+ is restricted to SEQ ID NO: 1, TROP2 binding domains comprising the same, conditionally active TROP2 binding proteins comprising the same, multivalent proteins comprising the same, active drugs comprising the same, processes for producing a multivalent protein comprising the same, processes for producing an active drug comprising the same, methods of increasing a therapeutic index of a TROP2 binding domain comprising the same, methods of increasing a therapeutic index of a TROP2 binding protein, methods of increasing a therapeutic index of a TROP2 binding protein comprising the same, and TROP2 targeting conditionally active multispecific proteins comprising the same. The first named invention has been selected based on the guidance set forth in section 10.54 of the PCT International Search and Preliminary Examination Guidelines. Specifically, the first named invention was selected based on the first listed compound species presented in the claims (see claim 3). It is believed that claims 1-3, 37, 67, 86, 101-103, 116-121, 128, 129, 137, and 139 read on this first named invention and thus these claims will be searched without fee to the extent that they read on.

Applicant is invited to elect additional SEQ ID NOs, TROP2 binding domains comprising the same, conditionally active TROP2 binding proteins comprising the same, multivalent proteins comprising the same, active drugs comprising the same, processes for producing a multivalent protein comprising the same, processes for producing an active drug comprising the same, methods of increasing a therapeutic index of a TROP2 binding domain comprising the same, methods of increasing a therapeutic index of a TROP2 binding protein, methods of increasing a therapeutic index of a TROP2 binding protein comprising the same, and TROP2 targeting conditionally active multispecific proteins comprising the same to be searched in a specific combination by paying an additional fee for each election. An exemplary election would be SEQ ID NO: 2, TROP2 binding domains comprising the same, conditionally active TROP2 binding proteins comprising the same, multivalent proteins comprising the same, active drugs comprising the same, processes for producing a

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

multivalent protein comprising the same, processes for producing an active drug comprising the same, methods of increasing a therapeutic index of a TROP2 binding domain comprising the same, methods of increasing a therapeutic index of a TROP2 binding protein, methods of increasing a therapeutic index of a TROP2 binding protein comprising the same, and TROP2 targeting conditionally active multispecific proteins comprising the same. Additional will be searched upon the payment of additional fees. Applicants must specify the claims that read on any additional elected inventions. Applicants must further indicate, if applicable, the claims which read on the first named invention if different than what was indicated above for this group. Failure to clearly identify how any paid additional invention fees are to be applied to the "+" group(s) will result in only the first claimed invention to be searched/examined.

The inventions listed in Groups I+ do not relate to a single general inventive concept under PCT Rule 13.1, because under PCT Rule 13.2 they lack the same or corresponding special technical features for the following reasons:

The Groups I+ formulas do not share a significant structural element responsible for TROP2 binding, requiring the selection of alternative amino acid sequences where the TROP2 binding domain "compris[es] an amino acid sequence that is at least about 75% identical to a sequence selected from the group consisting of SEQ ID NOS: 1-57."

Additionally, even if Groups I+ were considered to share the technical features of a TROP2 binding domain comprising a complementarity determining region 1 (CDR1), a CDR2, and a CDR3; A conditionally active TROP2 binding protein comprising a binding moiety (M) which comprises a non-CDR loop, a cleavable linker (L), a first target antigen binding domain (T1), and a second target antigen binding domain (T2), wherein at least one of the first target antigen binding domain (T1) and the second target antigen binding domain (T2) comprises a TROP2 binding domain, wherein the TROP2 binding domain comprises a complementarity determining region 1 (CDR1), a CDR2, and a CDR3, wherein the non-CDR loop is capable of binding to the TROP2 binding domain or the second target antigen binding domain, and wherein the binding moiety is capable of masking or masks the binding of the TROP2 binding domain or the second target antigen binding domain to its target; A multivalent protein; An active drug; A process for producing a multivalent protein, said process comprising culturing a host transformed or transfected with a vector comprising one or more nucleic acid sequences encoding the domains of the multivalent protein, under conditions allowing the expression of the multivalent protein and recovering and purifying the produced protein from the culture; A process for producing an active drug, said process comprising culturing a host transformed or transfected with a vector comprising one or more nucleic acid sequences encoding the domains of the active drug, under conditions allowing the expression of the active drug and recovering and purifying the produced drug from the culture; A method of increasing a therapeutic index of a TROP2 binding domain, the method comprising conjugating the TROP2 binding domain to a binding moiety comprising a cleavable linker and a non-CDR loop, - wherein the non-CDR loop comprises a binding site specific for the TROP2 binding domain, - wherein the TROP2 binding domain is masked from binding its target by the binding moiety, and - wherein the TROP2 binding domain binds its target upon cleavage of the cleavable linker; A method of increasing a therapeutic index of a TROP2 binding protein comprising a first target antigen binding domain and a second target antigen binding domain, wherein at least one of the first and the second target antigen binding domain comprises a TROP2 binding domain, the method comprising conjugating the first or the second target antigen binding domain to a binding moiety comprising a cleavable linker and a non-CDR loop, - wherein the non-CDR loop comprises a binding site specific for the first or the second target antigen binding domain, - wherein at least one of the first or the second target antigen binding domain is masked from binding its target by the binding moiety, and - wherein the first or the second target antigen binding domain that is masked, binds its target upon cleavage of the cleavable linker; A method of increasing a therapeutic index of a TROP2 binding protein comprising a TROP2 binding domain and a CD3 binding domain, the method comprising conjugating CD3 binding domain to a binding moiety comprising a cleavable linker and a non-CDR loop, wherein the non-CDR loop comprises a binding site specific for CD3 binding domain; and A TROP2 targeting conditionally active multispecific protein, comprising: a TROP2 binding domain, a CD3 binding domain, an albumin binding domain, wherein the albumin binding domain comprises a non-CDR loops that comprises a binding site specific for the CD3 binding domain and a cleavable linker, wherein the TROP2 binding domain comprises a complementarity determining region 1 (CDR1), a CDR2, and a CDR3, these shared technical features do not represent a contribution over the prior art.

Specifically, US 2021/0292421 A1 to Harpoon Therapeutics Inc. teaches a TROP2 binding domain comprising a complementarity determining region 1 (CDR1), a CDR2, and a CDR3 (the target antigen domain binds to

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

a tumor antigen. In some embodiments, the tumor antigen comprises... Trop2, Para. [0006]; The variable domains of both light and heavy immunoglobulin chains contain three hypervariable loops, or complementarity-determining regions (CDRs). The three CDRs of a V domain (CDR1, CDR2, CDR3) cluster at one end of the beta barrel, Para. [0080]; A conditionally active TROP2 binding protein comprising a binding moiety (M) which comprises a non-CDR loop, a cleavable linker (L), a first target antigen binding domain (T1), and a second target antigen binding domain (T2), wherein at least one of the first target antigen binding domain (T1) and the second target antigen binding domain (T2) comprises a TROP2 binding domain, wherein the TROP2 binding domain comprises a complementarity determining region 1 (CDR1), a CDR2, and a CDR3, wherein the non-CDR loop is capable of binding to the TROP2 binding domain or the second target antigen binding domain, and wherein the binding moiety is capable of masking or masks the binding of the TROP2 binding domain or the second target antigen binding domain to its target (a conditionally active binding protein comprising a binding moiety (M) which comprises a non-CDR loop, a cleavable linker (L), a first target antigen binding domain (T1), and a second target antigen binding domain (T2), wherein the first target antigen binding domain (T1) comprises an immunoglobulin molecule, wherein the non-CDR loop is capable of binding to the first target antigen binding domain, and wherein the binding moiety is capable of masking the binding of the first target antigen binding domain to its target, Para. [0007]; the binding moiety is capable of masking the binding of the target antigen binding domain (such as an immunoglobulin molecule) or a non-immunoglobulin binding molecule to its target via specific intermolecular interactions between the binding moiety and the target antigen binding domain, Para. [0005]; the target antigen domain binds to a tumor antigen. In some embodiments, the tumor antigen comprises... Trop2, Para. [0006]; The variable domains of both light and heavy immunoglobulin chains contain three hypervariable loops, or complementarity-determining regions (CDRs). The three CDRs of a V domain (CDR1, CDR2, CDR3) cluster at one end of the beta barrel, Para. [0080]; A multivalent protein (a conditionally active binding protein comprising a binding moiety (M) which comprises a non-CDR loop, a cleavable linker (L), a first target antigen binding domain (T1), and a second target antigen binding domain (T2), Para. [0007]); An active drug (active drug, Para. [0055]); An active drug (active drug, Para. [0055]); A process for producing a multivalent protein, said process comprising culturing a host transformed or transfected with a vector comprising one or more nucleic acid sequences encoding the domains of the multivalent protein, under conditions allowing the expression of the multivalent protein and recovering and purifying the produced protein from the culture (the binding moieties or the conditionally active binding proteins comprising the binding moieties as described herein, in some embodiments, are produced by introducing vectors encoding the binding moieties or the binding proteins as described above into host cells and culturing said host cells under conditions whereby the binding moieties or the binding proteins, or domains thereof are expressed, Para. [0121]; Trispecific proteins purified from CHO host cells, Para. [0142]); A process for producing an active drug, said process comprising culturing a host transformed or transfected with a vector comprising one or more nucleic acid sequences encoding the domains of the active drug, under conditions allowing the expression of the active drug and recovering and purifying the produced drug from the culture (the binding moieties or the conditionally active binding proteins comprising the binding moieties as described herein, in some embodiments, are produced by introducing vectors encoding the binding moieties or the binding proteins as described above into host cells and culturing said host cells under conditions whereby the binding moieties or the binding proteins, or domains thereof are expressed, Para. [0121]; Trispecific proteins purified from CHO host cells, Para. [0142]); A method of increasing a therapeutic index of a TROP2 binding domain, the method comprising conjugating the TROP2 binding domain to a binding moiety comprising a cleavable linker and a non-CDR loop, - wherein the non-CDR loop comprises a binding site specific for the TROP2 binding domain, - wherein the TROP2 binding domain is masked from binding its target by the binding moiety, and - wherein the TROP2 binding domain binds its target upon cleavage of the cleavable linker (The conditionally active binding proteins described in the present disclosure exhibit improved the binding affinities towards the target, for example a tumor antigen expressed on a cell surface, Para. [0111]; a conditionally active binding protein comprising a binding moiety (M) which comprises a non-CDR loop, a cleavable linker (L), a first target antigen binding domain (T1), and a second target antigen binding domain (T2), wherein the first target antigen binding domain (T1) comprises an immunoglobulin molecule, wherein the non-CDR loop is capable of binding to the first target antigen binding domain, and wherein the binding moiety is capable of masking the binding of the first target antigen binding domain to its target, Para. [0007]; the binding moiety is capable of masking the binding of the target antigen binding domain (such as an immunoglobulin molecule) or a non-immunoglobulin binding molecule to its target via specific intermolecular interactions between the binding moiety and the target antigen binding domain, Para. [0005]; the target antigen domain binds to a tumor antigen. In some embodiments, the tumor antigen comprises... Trop2, Para. [0006]; The variable domains of both light and heavy immunoglobulin chains contain three hypervariable loops, or complementarity-determining

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

regions (CDRs). The three CDRs of a V domain (CDR1, CDR2, CDR3) cluster at one end of the beta barrel, Para. [0080]); A method of increasing a therapeutic index of a TROP2 binding protein comprising a first target antigen binding domain and a second target antigen binding domain, wherein at least one of the first and the second target antigen binding domain comprises a TROP2 binding domain, the method comprising conjugating the first or the second target antigen binding domain to a binding moiety comprising a cleavable linker and a non-CDR loop, - wherein the non-CDR loop comprises a binding site specific for the first or the second target antigen binding domain, - wherein at least one of the first or the second target antigen binding domain is masked from binding its target by the binding moiety, and - wherein the first or the second target antigen binding domain that is masked, binds its target upon cleavage of the cleavable linker (The conditionally active binding proteins described in the present disclosure exhibit improved the binding affinities towards the target, for example a tumor antigen expressed on a cell surface, Para. [0111]; a conditionally active binding protein comprising a binding moiety (M) which comprises a non-CDR loop, a cleavable linker (L), a first target antigen binding domain (T1), and a second target antigen binding domain (T2), wherein the first target antigen binding domain (T1) comprises an immunoglobulin molecule, wherein the non-CDR loop is capable of binding to the first target antigen binding domain, and wherein the binding moiety is capable of masking the binding of the first target antigen binding domain to its target, Para. [0007]; the binding moiety is capable of masking the binding of the target antigen binding domain (such as an immunoglobulin molecule) or a non-immunoglobulin binding molecule to its target via specific intermolecular interactions between the binding moiety and the target antigen binding domain, Para. [0005]; the target antigen domain binds to a tumor antigen. In some embodiments, the tumor antigen comprises... Trop2, Para. [0006]; The variable domains of both light and heavy immunoglobulin chains contain three hypervariable loops, or complementarity-determining regions (CDRs). The three CDRs of a V domain (CDR1, CDR2, CDR3) cluster at one end of the beta barrel, Para. [0080]); A method of increasing a therapeutic index of a TROP2 binding protein comprising a TROP2 binding domain and a CD3 binding domain, the method comprising conjugating CD3 binding domain to a binding moiety comprising a cleavable linker and a non-CDR loop, wherein the non-CDR loop comprises a binding site specific for CD3 binding domain (The conditionally active binding proteins described in the present disclosure exhibit improved the binding affinities towards the target, for example a tumor antigen expressed on a cell surface, Para. [0111]; a conditionally active binding protein comprising a binding moiety (M) which comprises a non-CDR loop, a cleavable linker (L), a first target antigen binding domain (T1), and a second target antigen binding domain (T2), wherein the first target antigen binding domain (T1) comprises an immunoglobulin molecule, wherein the non-CDR loop is capable of binding to the first target antigen binding domain, and wherein the binding moiety is capable of masking the binding of the first target antigen binding domain to its target, Para. [0007]; the binding moiety is capable of masking the binding of the target antigen binding domain (such as an immunoglobulin molecule) or a non-immunoglobulin binding molecule to its target via specific intermolecular interactions between the binding moiety and the target antigen binding domain, Para. [0005]; the target antigen domain binds to a tumor antigen. In some embodiments, the tumor antigen comprises... Trop2, Para. [0006]; the first or the second target antigen binding domain binds to CD3, Para. [0008]; The variable domains of both light and heavy immunoglobulin chains contain three hypervariable loops, or complementarity-determining regions (CDRs). The three CDRs of a V domain (CDR1, CDR2, CDR3) cluster at one end of the beta barrel, Para. [0080]); and A TROP2 targeting conditionally active multispecific protein, comprising: a TROP2 binding domain, a CD3 binding domain, an albumin binding domain, wherein the albumin binding domain comprises a non-CDR loops that comprises a binding site specific for the CD3 binding domain and a cleavable linker, wherein the TROP2 binding domain comprises a complementarity determining region 1 (CDR1), a CDR2, and a CDR3 (a conditionally active binding protein comprising a binding moiety (M) which comprises a non-CDR loop, a cleavable linker (L), a first target antigen binding domain (T1), and a second target antigen binding domain (T2), wherein the first target antigen binding domain (T1) comprises an immunoglobulin molecule, wherein the non-CDR loop is capable of binding to the first target antigen binding domain, and wherein the binding moiety is capable of masking the binding of the first target antigen binding domain to its target, Para. [0007]; the binding moiety is capable of masking the binding of the target antigen binding domain (such as an immunoglobulin molecule) or a non-immunoglobulin binding molecule to its target via specific intermolecular interactions between the binding moiety and the target antigen binding domain, Para. [0005]; the target antigen domain binds to a tumor antigen. In some embodiments, the tumor antigen comprises... Trop2, Para. [0006]; the first or the second target antigen binding domain binds to CD3, Para. [0008]; The variable domains of both light and heavy immunoglobulin chains contain three hypervariable loops, or complementarity-determining regions (CDRs). The three CDRs of a V domain (CDR1, CDR2, CDR3) cluster at one end of the beta barrel, Para. [0080]).

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US2023/083985

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

The inventions listed in Groups I+ therefore lack unity under Rule 13 because they do not share a same or corresponding special technical features.

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of additional fees.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.: **1-3, 37, 67, 86, 101-103, 116-121, 128, 129, 137, 139**

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- ☐ The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US2023/083985

A. CLASSIFICATION OF SUBJECT MATTER

IPC: **C07K 16/28** (2024.01); **C07K 16/30** (2024.01); **C07K 19/00** (2024.01); **A61K 39/395** (2024.01); **A61P 35/00** (2024.01)
CPC: **C07K 16/2863**; **A61K 39/3955**; **C07K 16/2809**; **C07K 16/30**; **C07K 19/00**; **A61K 2039/505**; **A61P 35/00**; **C07K 2317/31**; **C07K 2319/50**

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

See Search History Document

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

See Search History Document

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

See Search History Document

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 2017/0174762 A1 (BOEHRINGER INGELHEIM INTERNATIONAL GMBH) 22 June 2017 (22.06.2017) entire document	1-3, 37, 67, 86, 101-103, 116-121, 128, 129, 137, 139
A	US 2021/0292421 A1 (HARPOON THERAPEUTICS INC.) 23 September 2021 (23.09.2021) entire document	1-3, 37, 67, 86, 101-103, 116-121, 128, 129, 137, 139
A	WO 2022/040128 A2 (MAVERICK THERAPEUTICS INC.) 24 February 2022 (24.02.2022) entire document	1-3, 37, 67, 86, 101-103, 116-121, 128, 129, 137, 139



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:

“A” document defining the general state of the art which is not considered to be of particular relevance
“D” document cited by the applicant in the international application
“E” earlier application or patent but published on or after the international filing date
“L” document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
“O” document referring to an oral disclosure, use, exhibition or other means
“P” document published prior to the international filing date but later than the priority date claimed

“T” later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

“X” document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

“Y” document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

“&” document member of the same patent family

Date of the actual completion of the international search

23 May 2024 (23.05.2024)

Date of mailing of the international search report

14 August 2024 (14.08.2024)

Name and mailing address of the ISA/US

**Mail Stop PCT, Attn: ISA/US
Commissioner for Patents
P.O. Box 1450, Alexandria, VA 22313-1450**

Facsimile No. **571-273-8300**

Authorized officer

**MATOS
TAINA**

Telephone No. **571-272-4300**

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US2023/083985

C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 2020/0055912 A1 (ORIONIS BIOSCIENCES NV et al.) 20 February 2020 (20.02.2020) entire document	1-3, 37, 67, 86, 101-103, 116-121, 128, 129, 137, 139
A	WO 2022/130013 A1 (TAKEDA PHARMACEUTICAL COMPANY LIMITED) 23 June 2022 (23.06.2022) entire document	1-3, 37, 67, 86, 101-103, 116-121, 128, 129, 137, 139